Royal Bank of Canada reaffirmed their sector perform rating on shares of Smith & Nephew (LON:SN – Get Rating) in a research note published on Tuesday morning, MarketBeat reports. Royal Bank of Canada currently has a GBX 1,500 ($18.12) target price on the stock.

SN has been the subject of a number of other research reports. Credit Suisse Group reduced their target price on shares of Smith & Nephew from GBX 1,540 ($18.61) to GBX 1,400 ($16.92) and set an outperform rating for the company in a research report on Thursday, August 4th. Barclays lowered their target price on shares of Smith & Nephew from GBX 1,630 ($19.70) to GBX 1,550 ($18.73) and set an overweight rating on the stock in a report on Thursday, August 4th. Berenberg Bank cut their price target on Smith & Nephew from GBX 1,800 ($21.75) to GBX 1,400 ($16.92) and set a buy rating for the company in a research note on Thursday, September 8th. Finally, JPMorgan Chase & Co. dropped their price objective on Smith & Nephew from GBX 1,442 ($17.42) to GBX 1,243 ($15.02) and set a neutral rating for the company in a report on Thursday, August 4th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Smith & Nephew currently has an average rating of Moderate Buy and an average target price of GBX 1,418.60 ($17.14).

Smith & Nephew Stock Performance

LON:SN opened at GBX 1,060 ($12.81) on Tuesday. The stock has a 50 day simple moving average of GBX 1,085.96 and a 200 day simple moving average of GBX 1,183.27. The stock has a market cap of £9.23 billion and a P/E ratio of 2,216.67. Smith & Nephew has a 1-year low of GBX 994.80 ($12.02) and a 1-year high of GBX 1,379.60 ($16.67). The company has a current ratio of 1.78, a quick ratio of 0.84 and a debt-to-equity ratio of 53.62.

Smith & Nephew Cuts Dividend

Insider Activity at Smith & Nephew

In related news, insider Erik Engstrom purchased 332 shares of Smith & Nephew stock in a transaction dated Tuesday, August 23rd. The shares were bought at an average cost of GBX 1,010 ($12.20) per share, for a total transaction of £3,353.20 ($4,051.72).

About Smith & Nephew

(Get Rating)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.

See Also

• Is There a Cure for What is Ailing Teladoc Stock?
• No One Told These 3 Stocks It's a Down Week
• Why Medical Products Maker Repligen May Be A Potential Buy
• At 10%, Is Arbor Realty Trust Dividend Worth It?
• Investors Should Tune Into RF Industries

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.